Supernus Pharmaceuticals, Inc. (SUPN)
NASDAQ: SUPN · Real-Time Price · USD
54.17
+0.30 (0.56%)
At close: Mar 9, 2026, 4:00 PM EDT
54.35
+0.18 (0.33%)
After-hours: Mar 9, 2026, 5:54 PM EDT
Supernus Pharmaceuticals Revenue
In the year 2025, Supernus Pharmaceuticals had annual revenue of $718.95M with 8.63% growth. Supernus Pharmaceuticals had revenue of $211.57M in the quarter ending December 31, 2025, with 21.48% growth.
Revenue (ttm)
$718.95M
Revenue Growth
+8.63%
P/S Ratio
4.24
Revenue / Employee
$924,103
Employees
778
Market Cap
3.12B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 718.95M | 57.14M | 8.63% |
| Dec 31, 2024 | 661.82M | 54.30M | 8.94% |
| Dec 31, 2023 | 607.52M | -59.72M | -8.95% |
| Dec 31, 2022 | 667.24M | 87.46M | 15.09% |
| Dec 31, 2021 | 579.78M | 59.38M | 11.41% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bausch Health Companies | 10.27B |
| Amneal Pharmaceuticals | 3.02B |
| Hims & Hers Health | 2.35B |
| Lantheus Holdings | 1.54B |
| Alkermes | 1.48B |
| Phibro Animal Health | 1.46B |
| Prestige Consumer Healthcare | 1.10B |
| BioCryst Pharmaceuticals | 874.84M |
SUPN News
- 12 days ago - Supernus Pharmaceuticals, Inc. (SUPN) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 13 days ago - Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 13 days ago - Supernus Pharmaceuticals to Participate in March Investor Conferences - GlobeNewsWire
- 25 days ago - Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026 - GlobeNewsWire
- 4 weeks ago - Lunai Bioworks, Inc. Issues Letter to Shareholders - PRNewsWire
- 5 weeks ago - Supernus: Outlook For 2026 Positive, Upholding Buy Rating - Seeking Alpha
- 7 weeks ago - These under-the-radar stocks combine fast growth with big upside potential - Market Watch
- 3 months ago - Supernus Pharmaceuticals, Inc. (SUPN) Presents at BofA Securities CNS Therapeutics Virtual Conference 2025 Transcript - Seeking Alpha